mRNA Therapeutics Market Forecasts to 2034 – Global Analysis By Therapy Type (Prophylactic mRNA Therapeutics, and Therapeutic mRNA Therapeutics), mRNA Construct Type (Conventional Non-replicating mRNA, Self-amplifying mRNA, Circular mRNA, and Trans-amplifying mRNA), Delivery System, Application, End User, Distribution Channel, and By Geography
According to Stratistics MRC, the Global mRNA Therapeutics Market is accounted for $13.0 billion in 2026 and is expected to reach $60.3 billion by 2034 growing at a CAGR of 21.1% during the forecast period. mRNA therapeutics utilize messenger RNA molecules to instruct cells to produce specific proteins that can prevent, treat, or cure diseases. This revolutionary approach gained global prominence through COVID-19 vaccines and is now expanding into oncology, rare diseases, and autoimmune disorders. Unlike traditional therapies, mRNA can be designed rapidly, scaled efficiently, and offers a versatile platform for personalized medicine. The market encompasses lipid nanoparticle delivery systems, modified mRNA sequences, and advanced manufacturing technologies that are reshaping the pharmaceutical landscape.
Market Dynamics:
Driver:
Unprecedented success of mRNA COVID-19 vaccines
The rapid development and global deployment of mRNA vaccines during the pandemic demonstrated the platform's speed, efficacy, and scalability, catalyzing unprecedented investment and regulatory confidence. Clinical success rates exceeding ninety percent for severe disease prevention validated mRNA technology as a viable therapeutic modality beyond niche applications. This breakthrough accelerated timelines for other mRNA candidates, with manufacturers leveraging established manufacturing infrastructure and cold chain logistics. Governments and private investors have committed billions to expand mRNA capabilities, creating a robust pipeline targeting respiratory syncytial virus, influenza, and cytomegalovirus. The pandemic effectively served as a large-scale real-world validation study, permanently elevating mRNA therapeutics from promising concept to mainstream medical solution.
Restraint:
Strict cold chain storage requirements
The inherent instability of mRNA molecules necessitates ultra-low temperature storage and specialized transportation infrastructure, limiting accessibility in resource-limited regions. Most mRNA formulations require temperatures between minus twenty and minus eighty degrees Celsius, demanding expensive freezers, temperature-controlled shipping containers, and continuous monitoring systems. Healthcare facilities lacking this infrastructure face significant barriers to adoption, creating disparities in access between developed and developing nations. While research into thermostable formulations is progressing, current commercial products remain dependent on complex cold chains. This logistical burden increases overall treatment costs and complicates emergency deployment scenarios, slowing market penetration in rural areas and lower-income countries where new therapies are often most needed.
Opportunity:
Expansion into personalized cancer vaccines
Advances in genomic sequencing and bioinformatics are enabling the development of individualized mRNA cancer vaccines tailored to each patient's unique tumor mutations. Neoantigen identification algorithms can now predict immunogenic targets, allowing manufacturers to design, produce, and administer patient-specific vaccines within weeks. Clinical trials in melanoma, non-small cell lung cancer, and pancreatic cancer have shown promising immune responses and survival benefits when combined with checkpoint inhibitors. This personalized approach transforms oncology from one-size-fits-all chemotherapy to precision immunotherapy. As manufacturing automation reduces production costs and turnaround times, personalized cancer vaccines represent a multi-billion dollar opportunity, potentially extending mRNA applications from prevention into curative treatment paradigms.
Threat:
Patent disputes and intellectual property litigation
The foundational intellectual property surrounding mRNA modification, lipid nanoparticle delivery, and manufacturing processes is subject to intense legal battles among key players. Disputes over core patents could restrict market access for developing companies, create licensing uncertainties, and increase legal costs across the industry. Court rulings that invalidate or narrow key patents may reduce incentives for continued innovation, while conversely, overly broad patent protection could stifle competition and maintain high prices. As the market matures, the resolution of these intellectual property conflicts will determine the competitive landscape, potentially delaying product launches and limiting the number of players capable of commercializing new mRNA therapies.
Covid-19 Impact:
The COVID-19 pandemic served as the definitive catalyst for mRNA therapeutics, compressing decades of potential development into just two years. Emergency use authorizations provided real-world safety data on millions of recipients, building regulatory frameworks for future approvals. Manufacturing capacity expanded exponentially, with new facilities constructed globally to meet vaccine demand, creating infrastructure now available for other mRNA products. Supply chain networks for raw materials including modified nucleotides and lipids matured substantially. The pandemic also fostered unprecedented collaboration between academic institutions, biotechnology companies, and government agencies, establishing partnerships that continue to advance the pipeline. Post-pandemic, the mRNA platform is positioned as a cornerstone of modern medicine rather than an experimental approach.
The Infectious Diseases segment is expected to be the largest during the forecast period
The Infectious Diseases segment is expected to account for the largest market share during the forecast period, building directly on the momentum established by COVID-19 vaccines. Beyond SARS-CoV-2, mRNA candidates targeting influenza, respiratory syncytial virus, human immunodeficiency virus, Zika virus, and cytomegalovirus are advancing through clinical development. Seasonal flu vaccines produced via mRNA offer potential advantages in manufacturing speed, allowing strain matching closer to flu season onset. Combination vaccines addressing multiple respiratory pathogens in a single injection are in development, simplifying immunization schedules. The established regulatory pathways for infectious disease vaccines, combined with government stockpiling programs and global health organization procurement, ensure this segment maintains dominance throughout the forecast timeline.
The Pharmaceutical & Biotechnology Companies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Pharmaceutical & Biotechnology Companies segment is predicted to witness the highest growth rate, driven by aggressive pipeline expansion and manufacturing scale-up activities. Major pharmaceutical corporations are investing heavily in mRNA platforms, establishing in-house capabilities through both internal development and strategic acquisitions of specialized biotech firms. These companies are pursuing diverse applications beyond infectious diseases, including oncology, rare genetic disorders, and autoimmune conditions, leveraging mRNA's programmability. The segment benefits from substantial research and development budgets, existing commercial infrastructure, and regulatory expertise. As approved mRNA products transition from clinical trials to commercial launches, pharmaceutical and biotechnology companies capture increasing value, making this the fastest-growing end-user category.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, anchored by substantial government funding, a mature biotechnology ecosystem, and early adoption of COVID-19 vaccines. The United States invested billions through Operation Warp Speed and subsequent initiatives, creating domestic manufacturing capacity and supporting clinical research. Leading mRNA companies are headquartered in the region, maintaining intellectual property portfolios and production facilities. Regulatory agencies have established clear guidance pathways for mRNA products, reducing approval uncertainty. Strong healthcare infrastructure capable of meeting cold chain requirements further supports adoption. The combination of innovation leadership, manufacturing scale, and favorable reimbursement policies ensures North America's dominant market position throughout the forecast period.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by aggressive government investments in local manufacturing capacity and expanding clinical research infrastructure. China has prioritized mRNA technology development, with domestic companies advancing candidates for multiple indications and constructing large-scale production facilities. Japan, South Korea, and India are similarly investing in platform capabilities, recognizing mRNA's strategic importance for pandemic preparedness and chronic disease management. Large populations with high infectious disease burdens create substantial addressable markets for mRNA vaccines. Additionally, contract manufacturing organizations in the region are scaling operations to serve global pharmaceutical clients, accelerating technology transfer and workforce training, positioning Asia Pacific as the fastest-growing market for mRNA therapeutics.
Key players in the market
Some of the key players in MRNA Therapeutics Market include Moderna Inc., BioNTech SE, CureVac N.V., Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, AstraZeneca plc, Arcturus Therapeutics Holdings Inc., Translate Bio Inc., eTheRNA immunotherapies NV, Gritstone bio Inc., Sangamo Therapeutics Inc., Argos Therapeutics Inc., Ethris GmbH, Panacea Biotec Limited and Takeda Pharmaceutical Company Limited.
Key Developments:
In April 2026, Moderna announced the initiation of a Phase 3 study for its investigational mRNA-based H5 pandemic influenza vaccine (mRNA-1018), with the first participants dosed in the U.S. and UK to address avian flu threats.
In March 2026, BioNTech outlined its 'catalyst-rich' 2026 roadmap, aiming to have 15 Phase 3 clinical trials ongoing by year-end, specifically focusing on mRNA cancer immunotherapies and antibody-drug conjugates (ADCs).
In August 2025, Pfizer and BioNTech received FDA approval for their updated 2025-2026 formula COVID-19 vaccine, tailored to the KP.2 variant, maintaining their lead in the prophylactic mRNA vaccine segment.
Therapy Types Covered:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
Market Dynamics:
Driver:
Unprecedented success of mRNA COVID-19 vaccines
The rapid development and global deployment of mRNA vaccines during the pandemic demonstrated the platform's speed, efficacy, and scalability, catalyzing unprecedented investment and regulatory confidence. Clinical success rates exceeding ninety percent for severe disease prevention validated mRNA technology as a viable therapeutic modality beyond niche applications. This breakthrough accelerated timelines for other mRNA candidates, with manufacturers leveraging established manufacturing infrastructure and cold chain logistics. Governments and private investors have committed billions to expand mRNA capabilities, creating a robust pipeline targeting respiratory syncytial virus, influenza, and cytomegalovirus. The pandemic effectively served as a large-scale real-world validation study, permanently elevating mRNA therapeutics from promising concept to mainstream medical solution.
Restraint:
Strict cold chain storage requirements
The inherent instability of mRNA molecules necessitates ultra-low temperature storage and specialized transportation infrastructure, limiting accessibility in resource-limited regions. Most mRNA formulations require temperatures between minus twenty and minus eighty degrees Celsius, demanding expensive freezers, temperature-controlled shipping containers, and continuous monitoring systems. Healthcare facilities lacking this infrastructure face significant barriers to adoption, creating disparities in access between developed and developing nations. While research into thermostable formulations is progressing, current commercial products remain dependent on complex cold chains. This logistical burden increases overall treatment costs and complicates emergency deployment scenarios, slowing market penetration in rural areas and lower-income countries where new therapies are often most needed.
Opportunity:
Expansion into personalized cancer vaccines
Advances in genomic sequencing and bioinformatics are enabling the development of individualized mRNA cancer vaccines tailored to each patient's unique tumor mutations. Neoantigen identification algorithms can now predict immunogenic targets, allowing manufacturers to design, produce, and administer patient-specific vaccines within weeks. Clinical trials in melanoma, non-small cell lung cancer, and pancreatic cancer have shown promising immune responses and survival benefits when combined with checkpoint inhibitors. This personalized approach transforms oncology from one-size-fits-all chemotherapy to precision immunotherapy. As manufacturing automation reduces production costs and turnaround times, personalized cancer vaccines represent a multi-billion dollar opportunity, potentially extending mRNA applications from prevention into curative treatment paradigms.
Threat:
Patent disputes and intellectual property litigation
The foundational intellectual property surrounding mRNA modification, lipid nanoparticle delivery, and manufacturing processes is subject to intense legal battles among key players. Disputes over core patents could restrict market access for developing companies, create licensing uncertainties, and increase legal costs across the industry. Court rulings that invalidate or narrow key patents may reduce incentives for continued innovation, while conversely, overly broad patent protection could stifle competition and maintain high prices. As the market matures, the resolution of these intellectual property conflicts will determine the competitive landscape, potentially delaying product launches and limiting the number of players capable of commercializing new mRNA therapies.
Covid-19 Impact:
The COVID-19 pandemic served as the definitive catalyst for mRNA therapeutics, compressing decades of potential development into just two years. Emergency use authorizations provided real-world safety data on millions of recipients, building regulatory frameworks for future approvals. Manufacturing capacity expanded exponentially, with new facilities constructed globally to meet vaccine demand, creating infrastructure now available for other mRNA products. Supply chain networks for raw materials including modified nucleotides and lipids matured substantially. The pandemic also fostered unprecedented collaboration between academic institutions, biotechnology companies, and government agencies, establishing partnerships that continue to advance the pipeline. Post-pandemic, the mRNA platform is positioned as a cornerstone of modern medicine rather than an experimental approach.
The Infectious Diseases segment is expected to be the largest during the forecast period
The Infectious Diseases segment is expected to account for the largest market share during the forecast period, building directly on the momentum established by COVID-19 vaccines. Beyond SARS-CoV-2, mRNA candidates targeting influenza, respiratory syncytial virus, human immunodeficiency virus, Zika virus, and cytomegalovirus are advancing through clinical development. Seasonal flu vaccines produced via mRNA offer potential advantages in manufacturing speed, allowing strain matching closer to flu season onset. Combination vaccines addressing multiple respiratory pathogens in a single injection are in development, simplifying immunization schedules. The established regulatory pathways for infectious disease vaccines, combined with government stockpiling programs and global health organization procurement, ensure this segment maintains dominance throughout the forecast timeline.
The Pharmaceutical & Biotechnology Companies segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Pharmaceutical & Biotechnology Companies segment is predicted to witness the highest growth rate, driven by aggressive pipeline expansion and manufacturing scale-up activities. Major pharmaceutical corporations are investing heavily in mRNA platforms, establishing in-house capabilities through both internal development and strategic acquisitions of specialized biotech firms. These companies are pursuing diverse applications beyond infectious diseases, including oncology, rare genetic disorders, and autoimmune conditions, leveraging mRNA's programmability. The segment benefits from substantial research and development budgets, existing commercial infrastructure, and regulatory expertise. As approved mRNA products transition from clinical trials to commercial launches, pharmaceutical and biotechnology companies capture increasing value, making this the fastest-growing end-user category.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share, anchored by substantial government funding, a mature biotechnology ecosystem, and early adoption of COVID-19 vaccines. The United States invested billions through Operation Warp Speed and subsequent initiatives, creating domestic manufacturing capacity and supporting clinical research. Leading mRNA companies are headquartered in the region, maintaining intellectual property portfolios and production facilities. Regulatory agencies have established clear guidance pathways for mRNA products, reducing approval uncertainty. Strong healthcare infrastructure capable of meeting cold chain requirements further supports adoption. The combination of innovation leadership, manufacturing scale, and favorable reimbursement policies ensures North America's dominant market position throughout the forecast period.
Region with highest CAGR:
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by aggressive government investments in local manufacturing capacity and expanding clinical research infrastructure. China has prioritized mRNA technology development, with domestic companies advancing candidates for multiple indications and constructing large-scale production facilities. Japan, South Korea, and India are similarly investing in platform capabilities, recognizing mRNA's strategic importance for pandemic preparedness and chronic disease management. Large populations with high infectious disease burdens create substantial addressable markets for mRNA vaccines. Additionally, contract manufacturing organizations in the region are scaling operations to serve global pharmaceutical clients, accelerating technology transfer and workforce training, positioning Asia Pacific as the fastest-growing market for mRNA therapeutics.
Key players in the market
Some of the key players in MRNA Therapeutics Market include Moderna Inc., BioNTech SE, CureVac N.V., Pfizer Inc., Sanofi SA, GlaxoSmithKline plc, AstraZeneca plc, Arcturus Therapeutics Holdings Inc., Translate Bio Inc., eTheRNA immunotherapies NV, Gritstone bio Inc., Sangamo Therapeutics Inc., Argos Therapeutics Inc., Ethris GmbH, Panacea Biotec Limited and Takeda Pharmaceutical Company Limited.
Key Developments:
In April 2026, Moderna announced the initiation of a Phase 3 study for its investigational mRNA-based H5 pandemic influenza vaccine (mRNA-1018), with the first participants dosed in the U.S. and UK to address avian flu threats.
In March 2026, BioNTech outlined its 'catalyst-rich' 2026 roadmap, aiming to have 15 Phase 3 clinical trials ongoing by year-end, specifically focusing on mRNA cancer immunotherapies and antibody-drug conjugates (ADCs).
In August 2025, Pfizer and BioNTech received FDA approval for their updated 2025-2026 formula COVID-19 vaccine, tailored to the KP.2 variant, maintaining their lead in the prophylactic mRNA vaccine segment.
Therapy Types Covered:
- Prophylactic mRNA Therapeutics
- Therapeutic mRNA Therapeutics
- Conventional Non-replicating mRNA
- Self-amplifying mRNA
- Circular mRNA
- Trans-amplifying mRNA
- Lipid Nanoparticles
- Polymer-based Systems
- Cationic Nano-emulsions
- Viral Vectors
- Other Delivery Systems
- Infectious Diseases
- Oncology
- Autoimmune Diseases
- Rare & Genetic Disorders
- Other Applications
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Research & Academic Institutes
- Contract Research Organizations
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Direct Procurement
- North America
- United States
- Canada
- Mexico
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Netherlands
- Belgium
- Sweden
- Switzerland
- Poland
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Vietnam
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Chile
- Peru
- Rest of South America
- Rest of the World (RoW)
- Middle East
- Saudi Arabia
- United Arab Emirates
- Qatar
- Israel
- Rest of Middle East
- Africa
- South Africa
- Egypt
- Morocco
- Rest of Africa
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
- Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
- Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
- Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
1 EXECUTIVE SUMMARY
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL MRNA THERAPEUTICS MARKET, BY THERAPY TYPE
5.1 Prophylactic mRNA Therapeutics
5.2 Therapeutic mRNA Therapeutics
6 GLOBAL MRNA THERAPEUTICS MARKET, BY MRNA CONSTRUCT TYPE
6.1 Conventional Non-replicating mRNA
6.2 Self-amplifying mRNA
6.3 Circular mRNA
6.4 Trans-amplifying mRNA
7 GLOBAL MRNA THERAPEUTICS MARKET, BY DELIVERY SYSTEM
7.1 Lipid Nanoparticles
7.2 Polymer-based Systems
7.3 Cationic Nano-emulsions
7.4 Viral Vectors
7.5 Other Delivery Systems
8 GLOBAL MRNA THERAPEUTICS MARKET, BY APPLICATION
8.1 Infectious Diseases
8.2 Oncology
8.3 Autoimmune Diseases
8.4 Rare & Genetic Disorders
8.5 Other Applications
9 GLOBAL MRNA THERAPEUTICS MARKET, BY END USER
9.1 Hospitals & Clinics
9.2 Pharmaceutical & Biotechnology Companies
9.3 Research & Academic Institutes
9.4 Contract Research Organizations
10 GLOBAL MRNA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
10.1 Hospital Pharmacies
10.2 Retail Pharmacies
10.3 Online Pharmacies
10.4 Direct Procurement
11 GLOBAL MRNA THERAPEUTICS MARKET, BY GEOGRAPHY
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 STRATEGIC MARKET INTELLIGENCE
12.1 Industry Value Network and Supply Chain Assessment
12.2 White-Space and Opportunity Mapping
12.3 Product Evolution and Market Life Cycle Analysis
12.4 Channel, Distributor, and Go-to-Market Assessment
13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
13.1 Mergers and Acquisitions
13.2 Partnerships, Alliances, and Joint Ventures
13.3 New Product Launches and Certifications
13.4 Capacity Expansion and Investments
13.5 Other Strategic Initiatives
14 COMPANY PROFILES
14.1 Moderna Inc.
14.2 BioNTech SE
14.3 CureVac N.V.
14.4 Pfizer Inc.
14.5 Sanofi SA
14.6 GlaxoSmithKline plc
14.7 AstraZeneca plc
14.8 Arcturus Therapeutics Holdings Inc.
14.9 Translate Bio Inc.
14.10 eTheRNA immunotherapies NV
14.11 Gritstone bio Inc.
14.12 Sangamo Therapeutics Inc.
14.13 Argos Therapeutics Inc.
14.14 Ethris GmbH
14.15 Panacea Biotec Limited
14.16 Takeda Pharmaceutical Company Limited
1.1 Market Snapshot and Key Highlights
1.2 Growth Drivers, Challenges, and Opportunities
1.3 Competitive Landscape Overview
1.4 Strategic Insights and Recommendations
2 RESEARCH FRAMEWORK
2.1 Study Objectives and Scope
2.2 Stakeholder Analysis
2.3 Research Assumptions and Limitations
2.4 Research Methodology
2.4.1 Data Collection (Primary and Secondary)
2.4.2 Data Modeling and Estimation Techniques
2.4.3 Data Validation and Triangulation
2.4.4 Analytical and Forecasting Approach
3 MARKET DYNAMICS AND TREND ANALYSIS
3.1 Market Definition and Structure
3.2 Key Market Drivers
3.3 Market Restraints and Challenges
3.4 Growth Opportunities and Investment Hotspots
3.5 Industry Threats and Risk Assessment
3.6 Technology and Innovation Landscape
3.7 Emerging and High-Growth Markets
3.8 Regulatory and Policy Environment
3.9 Impact of COVID-19 and Recovery Outlook
4 COMPETITIVE AND STRATEGIC ASSESSMENT
4.1 Porter's Five Forces Analysis
4.1.1 Supplier Bargaining Power
4.1.2 Buyer Bargaining Power
4.1.3 Threat of Substitutes
4.1.4 Threat of New Entrants
4.1.5 Competitive Rivalry
4.2 Market Share Analysis of Key Players
4.3 Product Benchmarking and Performance Comparison
5 GLOBAL MRNA THERAPEUTICS MARKET, BY THERAPY TYPE
5.1 Prophylactic mRNA Therapeutics
5.2 Therapeutic mRNA Therapeutics
6 GLOBAL MRNA THERAPEUTICS MARKET, BY MRNA CONSTRUCT TYPE
6.1 Conventional Non-replicating mRNA
6.2 Self-amplifying mRNA
6.3 Circular mRNA
6.4 Trans-amplifying mRNA
7 GLOBAL MRNA THERAPEUTICS MARKET, BY DELIVERY SYSTEM
7.1 Lipid Nanoparticles
7.2 Polymer-based Systems
7.3 Cationic Nano-emulsions
7.4 Viral Vectors
7.5 Other Delivery Systems
8 GLOBAL MRNA THERAPEUTICS MARKET, BY APPLICATION
8.1 Infectious Diseases
8.2 Oncology
8.3 Autoimmune Diseases
8.4 Rare & Genetic Disorders
8.5 Other Applications
9 GLOBAL MRNA THERAPEUTICS MARKET, BY END USER
9.1 Hospitals & Clinics
9.2 Pharmaceutical & Biotechnology Companies
9.3 Research & Academic Institutes
9.4 Contract Research Organizations
10 GLOBAL MRNA THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
10.1 Hospital Pharmacies
10.2 Retail Pharmacies
10.3 Online Pharmacies
10.4 Direct Procurement
11 GLOBAL MRNA THERAPEUTICS MARKET, BY GEOGRAPHY
11.1 North America
11.1.1 United States
11.1.2 Canada
11.1.3 Mexico
11.2 Europe
11.2.1 United Kingdom
11.2.2 Germany
11.2.3 France
11.2.4 Italy
11.2.5 Spain
11.2.6 Netherlands
11.2.7 Belgium
11.2.8 Sweden
11.2.9 Switzerland
11.2.10 Poland
11.2.11 Rest of Europe
11.3 Asia Pacific
11.3.1 China
11.3.2 Japan
11.3.3 India
11.3.4 South Korea
11.3.5 Australia
11.3.6 Indonesia
11.3.7 Thailand
11.3.8 Malaysia
11.3.9 Singapore
11.3.10 Vietnam
11.3.11 Rest of Asia Pacific
11.4 South America
11.4.1 Brazil
11.4.2 Argentina
11.4.3 Colombia
11.4.4 Chile
11.4.5 Peru
11.4.6 Rest of South America
11.5 Rest of the World (RoW)
11.5.1 Middle East
11.5.1.1 Saudi Arabia
11.5.1.2 United Arab Emirates
11.5.1.3 Qatar
11.5.1.4 Israel
11.5.1.5 Rest of Middle East
11.5.2 Africa
11.5.2.1 South Africa
11.5.2.2 Egypt
11.5.2.3 Morocco
11.5.2.4 Rest of Africa
12 STRATEGIC MARKET INTELLIGENCE
12.1 Industry Value Network and Supply Chain Assessment
12.2 White-Space and Opportunity Mapping
12.3 Product Evolution and Market Life Cycle Analysis
12.4 Channel, Distributor, and Go-to-Market Assessment
13 INDUSTRY DEVELOPMENTS AND STRATEGIC INITIATIVES
13.1 Mergers and Acquisitions
13.2 Partnerships, Alliances, and Joint Ventures
13.3 New Product Launches and Certifications
13.4 Capacity Expansion and Investments
13.5 Other Strategic Initiatives
14 COMPANY PROFILES
14.1 Moderna Inc.
14.2 BioNTech SE
14.3 CureVac N.V.
14.4 Pfizer Inc.
14.5 Sanofi SA
14.6 GlaxoSmithKline plc
14.7 AstraZeneca plc
14.8 Arcturus Therapeutics Holdings Inc.
14.9 Translate Bio Inc.
14.10 eTheRNA immunotherapies NV
14.11 Gritstone bio Inc.
14.12 Sangamo Therapeutics Inc.
14.13 Argos Therapeutics Inc.
14.14 Ethris GmbH
14.15 Panacea Biotec Limited
14.16 Takeda Pharmaceutical Company Limited
LIST OF TABLES
Table 1 Global mRNA Therapeutics Market Outlook, By Region (2023–2034) ($MN)
Table 2 Global mRNA Therapeutics Market Outlook, By Therapy Type (2023–2034) ($MN)
Table 3 Global mRNA Therapeutics Market Outlook, By Prophylactic mRNA Therapeutics (2023–2034) ($MN)
Table 4 Global mRNA Therapeutics Market Outlook, By Therapeutic mRNA Therapeutics (2023–2034) ($MN)
Table 5 Global mRNA Therapeutics Market Outlook, By mRNA Construct Type (2023–2034) ($MN)
Table 6 Global mRNA Therapeutics Market Outlook, By Conventional Non-replicating mRNA (2023–2034) ($MN)
Table 7 Global mRNA Therapeutics Market Outlook, By Self-amplifying mRNA (2023–2034) ($MN)
Table 8 Global mRNA Therapeutics Market Outlook, By Circular mRNA (2023–2034) ($MN)
Table 9 Global mRNA Therapeutics Market Outlook, By Trans-amplifying mRNA (2023–2034) ($MN)
Table 10 Global mRNA Therapeutics Market Outlook, By Delivery System (2023–2034) ($MN)
Table 11 Global mRNA Therapeutics Market Outlook, By Lipid Nanoparticles (2023–2034) ($MN)
Table 12 Global mRNA Therapeutics Market Outlook, By Polymer-based Systems (2023–2034) ($MN)
Table 13 Global mRNA Therapeutics Market Outlook, By Cationic Nano-emulsions (2023–2034) ($MN)
Table 14 Global mRNA Therapeutics Market Outlook, By Viral Vectors (2023–2034) ($MN)
Table 15 Global mRNA Therapeutics Market Outlook, By Other Delivery Systems (2023–2034) ($MN)
Table 16 Global mRNA Therapeutics Market Outlook, By Application (2023–2034) ($MN)
Table 17 Global mRNA Therapeutics Market Outlook, By Infectious Diseases (2023–2034) ($MN)
Table 18 Global mRNA Therapeutics Market Outlook, By Oncology (2023–2034) ($MN)
Table 19 Global mRNA Therapeutics Market Outlook, By Autoimmune Diseases (2023–2034) ($MN)
Table 20 Global mRNA Therapeutics Market Outlook, By Rare & Genetic Disorders (2023–2034) ($MN)
Table 21 Global mRNA Therapeutics Market Outlook, By Other Applications (2023–2034) ($MN)
Table 22 Global mRNA Therapeutics Market Outlook, By End User (2023–2034) ($MN)
Table 23 Global mRNA Therapeutics Market Outlook, By Hospitals & Clinics (2023–2034) ($MN)
Table 24 Global mRNA Therapeutics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023–2034) ($MN)
Table 25 Global mRNA Therapeutics Market Outlook, By Research & Academic Institutes (2023–2034) ($MN)
Table 26 Global mRNA Therapeutics Market Outlook, By Contract Research Organizations (2023–2034) ($MN)
Table 27 Global mRNA Therapeutics Market Outlook, By Distribution Channel (2023–2034) ($MN)
Table 28 Global mRNA Therapeutics Market Outlook, By Hospital Pharmacies (2023–2034) ($MN)
Table 29 Global mRNA Therapeutics Market Outlook, By Retail Pharmacies (2023–2034) ($MN)
Table 30 Global mRNA Therapeutics Market Outlook, By Online Pharmacies (2023–2034) ($MN)
Table 31 Global mRNA Therapeutics Market Outlook, By Direct Procurement (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
Table 1 Global mRNA Therapeutics Market Outlook, By Region (2023–2034) ($MN)
Table 2 Global mRNA Therapeutics Market Outlook, By Therapy Type (2023–2034) ($MN)
Table 3 Global mRNA Therapeutics Market Outlook, By Prophylactic mRNA Therapeutics (2023–2034) ($MN)
Table 4 Global mRNA Therapeutics Market Outlook, By Therapeutic mRNA Therapeutics (2023–2034) ($MN)
Table 5 Global mRNA Therapeutics Market Outlook, By mRNA Construct Type (2023–2034) ($MN)
Table 6 Global mRNA Therapeutics Market Outlook, By Conventional Non-replicating mRNA (2023–2034) ($MN)
Table 7 Global mRNA Therapeutics Market Outlook, By Self-amplifying mRNA (2023–2034) ($MN)
Table 8 Global mRNA Therapeutics Market Outlook, By Circular mRNA (2023–2034) ($MN)
Table 9 Global mRNA Therapeutics Market Outlook, By Trans-amplifying mRNA (2023–2034) ($MN)
Table 10 Global mRNA Therapeutics Market Outlook, By Delivery System (2023–2034) ($MN)
Table 11 Global mRNA Therapeutics Market Outlook, By Lipid Nanoparticles (2023–2034) ($MN)
Table 12 Global mRNA Therapeutics Market Outlook, By Polymer-based Systems (2023–2034) ($MN)
Table 13 Global mRNA Therapeutics Market Outlook, By Cationic Nano-emulsions (2023–2034) ($MN)
Table 14 Global mRNA Therapeutics Market Outlook, By Viral Vectors (2023–2034) ($MN)
Table 15 Global mRNA Therapeutics Market Outlook, By Other Delivery Systems (2023–2034) ($MN)
Table 16 Global mRNA Therapeutics Market Outlook, By Application (2023–2034) ($MN)
Table 17 Global mRNA Therapeutics Market Outlook, By Infectious Diseases (2023–2034) ($MN)
Table 18 Global mRNA Therapeutics Market Outlook, By Oncology (2023–2034) ($MN)
Table 19 Global mRNA Therapeutics Market Outlook, By Autoimmune Diseases (2023–2034) ($MN)
Table 20 Global mRNA Therapeutics Market Outlook, By Rare & Genetic Disorders (2023–2034) ($MN)
Table 21 Global mRNA Therapeutics Market Outlook, By Other Applications (2023–2034) ($MN)
Table 22 Global mRNA Therapeutics Market Outlook, By End User (2023–2034) ($MN)
Table 23 Global mRNA Therapeutics Market Outlook, By Hospitals & Clinics (2023–2034) ($MN)
Table 24 Global mRNA Therapeutics Market Outlook, By Pharmaceutical & Biotechnology Companies (2023–2034) ($MN)
Table 25 Global mRNA Therapeutics Market Outlook, By Research & Academic Institutes (2023–2034) ($MN)
Table 26 Global mRNA Therapeutics Market Outlook, By Contract Research Organizations (2023–2034) ($MN)
Table 27 Global mRNA Therapeutics Market Outlook, By Distribution Channel (2023–2034) ($MN)
Table 28 Global mRNA Therapeutics Market Outlook, By Hospital Pharmacies (2023–2034) ($MN)
Table 29 Global mRNA Therapeutics Market Outlook, By Retail Pharmacies (2023–2034) ($MN)
Table 30 Global mRNA Therapeutics Market Outlook, By Online Pharmacies (2023–2034) ($MN)
Table 31 Global mRNA Therapeutics Market Outlook, By Direct Procurement (2023–2034) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.
